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Abstract
The blood–brain barrier (BBB), which forms the interface between the blood and the cerebral parenchyma, has been shown
to be disrupted during retroviral-associated neuromyelopathies. Human T Lymphotropic Virus (HTLV-1) Associated
Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is a slowly progressive neurodegenerative disease associated with BBB
breakdown. The BBB is composed of three cell types: endothelial cells, pericytes and astrocytes. Although astrocytes have
been shown to be infected by HTLV-1, until now, little was known about the susceptibility of BBB endothelial cells to HTLV-1
infection and the impact of such an infection on BBB function. We first demonstrated that human cerebral endothelial cells
express the receptors for HTLV-1 (GLUT-1, Neuropilin-1 and heparan sulfate proteoglycans), both in vitro, in a human
cerebral endothelial cell line, and ex vivo, on spinal cord autopsy sections from HAM/TSP and non-infected control cases. In
situ hybridization revealed HTLV-1 transcripts associated with the vasculature in HAM/TSP. We were able to confirm that the
endothelial cells could be productively infected in vitro by HTLV-1 and that blocking of either HSPGs, Neuropilin 1 or Glut1
inhibits this process. The expression of the tight-junction proteins within the HTLV-1 infected endothelial cells was altered.
These cells were no longer able to form a functional barrier, since BBB permeability and lymphocyte passage through the
monolayer of endothelial cells were increased. This work constitutes the first report of susceptibility of human cerebral
endothelial cells to HTLV-1 infection, with implications for HTLV-1 passage through the BBB and subsequent deregulation of
the central nervous system homeostasis. We propose that the susceptibility of cerebral endothelial cells to retroviral
infection and subsequent BBB dysfunction is an important aspect of HAM/TSP pathogenesis and should be considered in
the design of future therapeutics strategies.
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Introduction
The Blood-Brain barrier (BBB) constitutes the interface between
the blood and the central nervous system (CNS). It is composed of
astrocytes, pericytes and brain microvascular endothelial cells.
This latter cell type forms the major structural and functional
element of the BBB, with endothelial cells sealed together with
Tight Junctions (TJs). Under physiological conditions, the BBB
maintains CNS homeostasis and selectively regulates intracellular
and paracellular passage of ions, molecules and cells [1].
BBB integrity is compromised during retroviral infection; for
example, BBB breakdown has been reported during Human
Immunodeficiency Virus Type 1 (HIV) infection, especially during
HIV-related encephalitis and HIV-associated dementia [2]. One
to three percent of the 20 million people infected worldwide by the
retrovirus HTLV-1 (for human T-lymphotropic virus type 1)
develop HTLV-Associated Myelopathy/Tropical Spastic Parapa-
resis (HAM/TSP) [3]. This is a slowly progressive paraplegia of
the lower extremities, involving demyelination and neuronal
degeneration mainly in the thoracic spinal cord. BBB disruption
has been attested in HAM/TSP patients by several lines of
evidence, such as fibrinogen leakage and IgG deposits in CNS
parenchyma [4] as well as lymphocyte passage through brain
endothelium [4–7]. As previously shown, BBB disruption is
associated with alterations in tight junctions between endothelial
cells in the vasculature of a HAM/TSP patient [8].
The mechanisms of BBB disruption during retroviral-associated
pathologies are not yet fully understood. Most studies focus on the
effect of soluble molecules secreted by infected lymphocytes on
BBB functions and intercellular TJ organization. In the case of
HIV infection, the viral protein Tat has been shown to induce an
inflammatory process in brain endothelial cells, or endothelial cell
apoptosis [9], and to be able to disrupt the intercellular TJs [10].
In the context of HTLV-1 infection, we recently demonstrated
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that proinflammatory cytokines, such as IL-1a and TNFa,
secreted by infected lymphocytes, are sufficient to disrupt TJs
between human brain endothelial cells and induce permeability
changes [8].
Alternative mechanisms could contribute to BBB dysfunction
associated with HTLV-1 infection. Although neurological disease
in mice infected with the PVC-211 Murine Leukemia Virus has
been associated with infection of brain endothelial cells [11], the
infection of brain endothelial cells by human retroviral agents and
its role in BBB breakdown is still a matter for debate. In the case of
HIV infection, a number of earlier studies reported infection of
endothelial cells in adult brain tissue [12–14], based upon
morphological appearance and vascular localization of cells found
positive by immunocytochemistry, in situ hybridization or PCR-in
situ hybridization for viral transcripts. Conflicting results were
obtained in vitro from brain-derived endothelial cells (for review,
see [15]).
In the case of HTLV-1, no evidence for infection of human
brain endothelial cells has been reported so far, most likely due to
the rarity of material from patients with HAM/TSP, and the low
level of HTLV-1 expression in tissues. Although an increased
adherence of T lymphocytes from HAM/TSP patients to human
brain endothelial cells has been observed [16], the main data
concern extra-neural endothelial cells: it has been demonstrated in
vitro that human venous endothelial cells derived from umbilical
cords are susceptible to HTLV-1 infection [17,18], and that
HTLV-1 proviral DNA could be detected in dermal endothelial
cells ex vivo [19].
In this study, we investigated the susceptibility of human brain
endothelial cells to HTLV-1 infection, and its possible conse-
quences on BBB integrity, both in vitro, in a human brain
endothelial cell line, and ex vivo on spinal cord autopsy sections
from HAM/TSP patients. We found that human brain endothelial
cells can be productively infected in vitro by HTLV-1, with
consequent alterations in the BBB, evidenced by increased
lymphocyte migration and passage of small molecules through
endothelium. These data provide a basis for and transient BBB
alterations that may be observed during BBB pathogenesis.
Results
Expression of HTLV-1 receptors within the spinal cord of
uninfected or HAM/TSP patients
Three cellular components have been identified as forming part
of the HTLV-1-entry complex: heparan sulfate proteoglycans
(HSPGs) [20,21], Neuropilin-1 [22], a co-receptor for VEGF165
and semaphorin 3a, and the glucose transporter Glut-1 [23].
The expression of HSPGs in BBB endothelial cells has
previously been reported; in vivo, HSPGs are ubiquitously
expressed at the cell surface or throughout the extracellular
matrix of all mammalian tissues [24]; in particular, HSPGs have
been previously detected in cerebral blood vessels [25].
In this study, we examined the expression of Glut-1 and
Neuropilin-1 in the endothelial cells that form the BBB in situ. As
HAM/TSP is characterized by lymphocyte infiltration and
inflammation mainly within the thoracic spinal cord, we focused
our investigation on this region.
In tissue sections derived from the thoracic spinal cord of
uninfected control cases, Glut-1 expression was diffuse and patchy
on fibres throughout the grey matter, intense on fibers in the
dorsal root and also detected in the meninges surrounding the cord
(Fig. 1A). Glut-1 was expressed prominently on blood-vessels
within both the white and the grey matter (Fig. 1A and B). The
Neuropilin-1 (NP-1) was expressed diffusely in the posterior, lateral
and anterior columns, and in the dorsolateral fasciculus/dorsal
root (Fig. 1D). Cellular expression was particularly noted at the
apex of the posterior column, and on motor neurons in the
anterior column (data not shown). Significantly, NP-1 was highly
Figure 1. Expression of HTLV-1 receptors, Glut-1 and NP-1, in
the thoracic spinal cord from an uninfected individual. (A,B)
Glut-1 immunostaining by immunoperoxydase technique (iPO) (DAB
substrate). (C) Dual staining for Glut-1 (iPO, DAB substrate, brown color)
and factor VIII (Alcaline phosphatase (AP), FastBlue substrate, blue
color). (D,E) NP-1 staining by iPO technique (DAB substrate). Thoracic
spinal cord specimens were cut in a cryostat, fixed in methanol and
processed for iPO as described in Materials and Methods. (F) Dual
staining for NP-1 (iPO, DAB substrate, brown color) and factor VIII
(Alcaline phosphatase, FastBlue substrate, blue color). Frozen tissue
samples from the thoracic spinal cord were cut on a cryostat at 10 mm,
fixed in methanol and processed for immunohistochemistry as
described in Materials and Methods. Magnification: (A,D) 56, (B–E)
506, (C–F) 1006.
doi:10.1371/journal.ppat.1000205.g001
Author Summary
The blood–brain barrier (BBB) forms the interface between
the blood and the central nervous system (CNS). BBB
disruption is considered to be a key event in the
pathogenesis of retroviral-associated neurological diseas-
es. The present paper deals with the susceptibility of the
endothelial cells (i.e., one of the main cellular components
of BBB) to retroviral infection, and with the impact of
infection in BBB function. This study focuses on the Human
T-Lymphotropic Virus (HTLV-1), which infects 20 million
people worldwide, and is the etiological agent of a
neurodegenerative disease called HTLV-1 Associated
Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). We
first demonstrated that the cerebral endothelial cells
express the receptors for the retrovirus in vitro, and on
spinal cord autopsy sections from non-infected and HAM/
TSP patients. We found on these latter that vascular-like
structures were infected and confirmed in vitro that the
endothelial cells could be productively infected by HTLV-1.
We demonstrated that such an infection impairs BBB
properties in vitro, as well as tight junctions, that are cell
adhesion structures. This study is the first to demonstrate
the impact of HTLV-1 infection on human BBB integrity;
such a susceptibility has to be considered in the design of
future therapeutics strategies.
HTLV-1 Infects Brain Endothelial Cells
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expressed on blood vessels, and within the meninges in all
segments of the thoracic spinal cord (Fig. 1D and E). Vascular
endothelial cell expression of Glut-1 and NP-1 was confirmed by
double immunolabeling with Factor VIII, a specific marker for
endothelial cells (Fig. 1C and F).
We then determined whether expression of these receptors by
endothelial cells was conserved in HAM/TSP. In tissue sections of
the thoracic spinal cord derived from HAM/TSP patients, Glut-1
immunoreactivity was detected in blood vessels, in the absence
(Fig. 2A) or presence of cell infiltrates (Fig. 2B and C). Neuropilin-
1 could also be detected in blood vessels in sections from HAM/
TSP patients (data not shown).
Since microvascular endothelial cells that constitute the BBB
express HTLV-1 receptors, we examined whether the infection of
these cells by HTLV-1 could be detected in situ, by performing in
situ hybridization for a viral mRNA (the messenger that encodes
the viral transactivator Tax) on the spinal cord sections. Cellular
infiltrates were positive for viral Tax mRNA (data not shown).
However, we focused our analyses on spinal cord regions where
the infiltrates were absent, to prevent the signal within the infected
lymphocytes from masking the signal from resident cells within the
CNS parenchyma. Since astrocytes are known to be targets of
HTLV-1 infection [26,27], the detection of a positive signal in
several GFAP immunoreactive cells constituted a suitable positive
control (Fig. 2D), as shown in previous studies [4]. We also
encountered rare positive signals associated with vascular
structures (Fig. 2E). This observation suggested the possibility of
infection of cerebral endothelial cells by HTLV-1.
Expression of HTLV-1 receptors by hCMEC/D3 cells
Although viral transcripts were found to be associated with
blood vessels, this observation could not be taken as definitive
evidence for the infection of endothelial cells forming the BBB
specifically as other cell types such as pericytes are closely
associated with endothelial cells. We therefore took advantage of a
human-derived brain endothelial cell line, hCMEC/D3, that had
been previously reported to retain many BBB characteristics [28].
We first investigated the expression of the 3 (co-)receptors for
HTLV-1 entry by flow cytometry analysis.
Glut-1 expression was highly detected in permeabilized
hCMEC/D3 cells. In order to detect expression of this protein
at the cell surface, immunostaining was performed on fixed but
non-permeabilized cells. The expression of Glut-1 at the cell
surface was detected in 31% of the hCMEC/D3 cells (Fig. 3A).
Similarly, cell surface expression of NP-1 and HSPGs were
detected in 82% and 59% of the hCMEC/D3 cells respectively
(Fig. 3B and C).
Infection of human cerebral endothelial cells hCMEC/D3
cells by HTLV-1
In order to determine if the expression of surface receptors on
endothelial cells allows HTLV-1 entry, we investigated whether
hCMEC/D3 cells could be infected by HTLV Env-pseudotyped
LacZ vectors. b-Gal production was detected upon infection of
hCMEC/D3 cells by A-MLV as well as by H-MLV pseudotypes.
Addition of serum from an uninfected donor did not reduce
infection by either pseudotype. In contrast, addition of serum from
an HTLV-1-infected HAM/TSP patient abolished the infection
by H-MLV, while high level of A-MLV pseudotype infection was
still observed (Fig. 3D). These results indicate that hCMEC/D3
cells allow HTLV Env-mediated entry.
The ability of a retrovirus such as HTLV-1 to enter a particular
cell type is usually correlated with the ability of target cells to fuse
and form syncytia with infected T lymphocytes. We therefore
quantified the number of syncytia in hCMEC/D3 and lymphocyte
cocultures. Whereas hCMEC/D3 did not fuse with C81-66
lymphocytes (HTLV-1-infected cells that do not express Env
glycoproteins), numerous syncytia were observed in co-cultures
with infected MT2 lymphocytes at 24 hours. The number of
nuclei per syncytium ranged from 3 to 11 (Fig. 4A). Syncytia were
found immunoreactive for viral p24 (Fig. 4C). In order to ascertain
the endothelial origin of the syncytia, we prestained the hCMEC/
Figure 2. Detection of Glut-1 and HTLV-1 transcripts in the thoracic spinal cord from HAM/TSP patient. (A,B,C) Glut-1 staining by iPO
(DAB substrate, brown) on thoracic spinal cord sections from a HAM/TSP patient. Nuclei were counterstained with Harri’s haematoxilin solution (blue).
(A,B) Cryostat section; (C) paraffin section. Magnification: (A) 306; (B,C) 756. (D,E) Detection of HTLV-1 transcripts (tax) in cryosections of the spinal
cord by in situ hybridization. Arrow heads indicate positive cells and vascular structures. Astrocytes were detected by iPO (DAB substrate, brown)
against GFAP. Magnification: 2206.
doi:10.1371/journal.ppat.1000205.g002
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D3 cells with a vital fluorescent molecule (CellTracker Red
CMTPX). Syncytia were shown to be fluorescently labeled
(Fig. 4D).
Addition of serum from an uninfected patient did not prevent
the formation of syncytia. In contrast, a dramatic reduction in the
number and the size of syncytia was observed when serum from an
HAM/TSP patient was added to the medium (Fig. 4A), showing
that the fusion is HTLV-mediated. Similarly, syncytia formation
could also be inhibited by addition of VEGF165, a physiological
ligand of NRP-1 that has been shown to inhibit the binding of the
HTLV-1 Env proteins to target cells [22], of dextran sulfate, an
inhibitor of HSPG-mediated HTLV-1 entry [20], or of an
antibody directed against the glucose transporter Glut-1 (Fig. 4B).
It is worth noting that no significant alterations in syncytia
formation were observed following addition of an irrelevant
isotype-matched antibody to the culture medium.
These data suggest that HTLV-1 entry into hCMEC/D3 cells is
dependent on the interactions between viral envelope proteins and
the three putative cellular receptors for HTLV-1 infection
(heparan sulfate proteoglycans, neuropilin-1 and Glut-1).
Human cerebral endothelial cells are productively
infected by HTLV-1
As HTLV-1 can enter hCMEC/D3 cells, we then determined
whether this event allows a productive infection. Endothelial cells
were co-cultivated with irradiated lymphocytes. The irradiation
dose was lethal for these cells, as confirmed by Trypan blue
staining which indicated that 100% of the lymphocytes were dead
by day 8 post-irradiation (data not shown).
HTLV p19 was detected in the supernatants of co-cultures but
decreased during the 10 first days: this correlated with lymphocyte
and syncytia cell death (data not shown). At 10 days post coculture,
no syncytium could be observed. From day 13 post-contact, p19
production to reach about 510 pg/day at day 22, indicating that
human brain endothelial cells produced viral proteins (Fig. 5A).
HTLV-1 productive infection could be prevented by addition of
AZT, an inhibitor for the reverse transcriptase, to the culture
medium. The percentage of positive endothelial cells for viral p24
increased in parallel to p19 levels detected in the supernatant
reach maximal infectivity rates at day 22, with 18% of the
endothelial cells positive for p24 (Fig. 5B). No cytopathic effect of
HTLV-1 infection endothelial cells was observed.
At day 22 post co-culture (2 days after renewal of the medium),
the supernatant was collected and ultracentrifuged. The pellet was
resuspended and added to culture medium of reporter 293T-LTR-
GFP cells. After 6 days of culture, fluorescent cells were visualized,
demonstrating the presence of Tax protein within these reporter
cells. Furthermore the fluorescent cells could form syncytia, and
expressed the viral envelope protein (Fig. 5C). In addition, the
number of the fluorescent cells was dramatically reduced (up to
37%) in the presence of AZT indicating that the detected
Figure 3. Expression of viral receptors at the cell surface of hCMEC/D3 cells and susceptibility to infection by HTLV-Env
pseudotyped particles. (A) FACS analysis of Glut-1 expression on hCMEC/D3 cells. Signal for permeabilized cells appear as bold-lined curve;
unpermeabilized as thin-lined curve; control cells (without Glut-1 antibody) appear as a grey-filled curve. (B) FACS analysis of Neuropilin-1 expression
on hCMEC/D3 cells. Signal for unpermeabilized as bold-lined curve; control cells (without NP-1 antibody) appear as a grey-filled curve. (C) FACS
analysis of Heparan sulfate-proteoglycans expression on hCMEC/D3 cells. Signal for unpermeabilized as bold-lined curve; control cells (without HSPGs
antibody) appear as a grey-filled curve. (D) Infection assay on hCMEC/D3 cells using Lac-Z-carrying MLV particles pseudotyped with the HTLV (HTLV)
or Amphotropic (MLV) envelope proteins. b-gal production was measured using chemiluminescence after subtracting the background of uninfected
cells on total protein normalization. Infections were performed without serum, or in the presence of serum from a HAM/TSP patient (HAM/TSP) (1/10)
or from a HTLV-uninfected individual (control) (1/10). Results represented as means6SD.
doi:10.1371/journal.ppat.1000205.g003
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fluorescence signal in 293T-LTR-GFP cells was specific to de novo
infection of reporter cells. These results indicate that cerebral
endothelial cells produced infectious viral particles.
Impairment of BBB functions following infection by
HTLV-1
Lastly, we assessed the impact of HTLV-1 infection of
endothelial cells on BBB function, by evaluating the paracellular
permeability of hCMEC/D3 cell monolayers and the transmigra-
tion of lymphocytes through the barrier in an infected and non-
infected context.
hCMEC/D3 cells, incubated with irradiated C81-66 (HTLV-1-
infected lymphocytes that are not productively infected) or with
MT2 cells 15 days prior to the experiment were seeded on filters and
allowed to reach confluence. The paracellular permeability of
monolayers of hCMEC/D3 cells infected with HTLV-1 was much
higher than the permeability of hCMEC/D3 cells previously
cocultured with control C81-66 T-lymphocytes (Fig. 6A). Similarly,
transmigration of uninfected T-lymphocytes (CEM and Jurkat)
across monolayers of hCMEC/D3 cells infected with HTLV-1 was
increased compared to that across a monolayer of uninfected
hCMEC/D3 cells (Fig. 6B). In addition, the migration of HTLV-1-
infected lymphocytic cell lines through hCMEC/D3 cells was
increased compared to control lymphocytes as previously reported
[8]. However, no differences in HTLV-1-infected lymphocyte
transmigration across HTLV-1-infected or non-infected hCMEC/
D3 cells were observed. These data indicate that HTLV-1-infection
of endothelial cells alters classical BBB functions.
We then analyzed the expression levels of proteins that
constitute the tight junctions by Western blot. As indicated in
Figure 4. Syncytia formation between hCMEC/D3 cells and HTLV-1 infected MT-2 lymphocytes at 24 h post-contact. (A) Role of the
viral proteins in the formation of the syncytia. Evaluation of the number and size (nb of nuclei/syncytium) of the syncytia obtained by coculture
between hCMEC/D3 and MT-2 cells in the presence of serum from a HAM/TSP patient (1/7) (noted HAM/TSP) or from an uninfected individual
(control, noted HTLV negative control or in the absence of any serum (w/o serum). (B) Role of the viral receptors in the formation of the syncytia.
Evaluation of the number and size (nb of nuclei/syncytium) of the syncytia obtained by coculture between hCMEC/D3 and MT-2 cells in the presence
of dextran sulfate in blue (that prevents the HTLV-1 Env/HSPG interaction), or in the presence of VEGF165 in green (that prevents the HTLV-1 Env/
NRP-1 interaction), or in the presence of a polyclonal antibody against Glut-1 in red (that prevents the HTLV-1 Env/GLUT1 interaction). Results are
representative of 3 independent experiments. (C) Detection of viral p24 protein (green) by immunofluorescence in a syncytium. Nuclei were stained
with DAPI (blue). (D) Demonstration of endothelial origin of the syncytia by prior labeling of hCMEC/D3 cells with a red vital fluorescent marker (Cell-
tracker, red). Nuclei were stained with DAPI (blue). Magnification (B–C): 3506.
doi:10.1371/journal.ppat.1000205.g004
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Fig. 6C, ZO-1 levels were dramatically reduced in HTLV-1-
infected hCMEC/D3 cells whereas, in the case of occludin, the
expression levels of the 55 kDa isoform, but not those of the
60 kDa isoform were decreased.
Since we have previously shown that the Myosin Light Chain
Kinase (MLCK) is important in tight junction regulation of
endothelial cells incubated with HTLV-1 infected lymphocytes, we
determined whether the inhibition of MLCK activity could
prevent long-term barrier impairment of HTLV-1 infected
endothelial cells (Fig. 6D). Treatment of the endothelial cells for
24 h with the MLCK inhibitor ML7 failed to restore low
paracellular permeability in HTLV-1 infected hCMEC/D3 cells.
The molecular mechanisms of TJ disruption in endothelial cells
induced by direct HTLV-1 infection appear to be different to
those induced by HTLV-1-infected lymphocytes, as previously
demonstrated [8].
Discussion
The BBB constitutes an interface between the bloodstream and
CNS parenchyma, and regulates the intracellular and paracellular
passage of molecules and cells between the two compartments [1].
Disruption of the BBB in HAM/TSP is strongly suggested by
observations of perivascular cuffing with lymphocyte and macro-
phage infiltrates [4,5,7], and confirmed by reports of fibrinogen
and IgG deposits in the CNS parenchyma of HAM/TSP patients
[4]. BBB breakdown is an important step in HAM/TSP
pathogenesis, especially by facilitating migration of lymphocytes
into the CNS. Infiltrated lymphocytes are believed to cause
demyelination and axonal degeneration that are hallmarks of
HTLV-1-associated neuropathology [29]. The mechanisms un-
derlying BBB alteration during HAM/TSP are not yet well
determined. In an in vitro model of the BBB, composed of human
cerebral microvascular endothelial cells [28], we previously
demonstrated the importance of proinflammatory cytokines
secreted by infected lymphocytes in the early stages of BBB
disruption [8,30]. In the present study we investigated whether
BBB endothelial cells were susceptible to HTLV-1 infection and
the impact of such an infection on BBB integrity.
BBB dysfunction associated with retroviral infections has been
previously described. In a murine model, the infection of brain
endothelial cells has been reported both in vitro and in vivo in the
case of PVC-211 murine leukemia virus (a neuropathogenic
variant of the Friend MuLV), with a direct correlation between the
replication efficiency of a virus in brain endothelial cells in vitro and
its ability to cause neurological disease in vivo [11]. Moreover, in
the case of infection by the Feline Immunodeficiency Virus,
infection of brain endothelial cells has been proposed to represent
one of the ways of viral entry into the CNS [31]. Meanwhile,
infection of brain endothelial cells by human retroviral agents is
still a matter of debate. In the case of HIV infection, previous
studies have reported infection of endothelial cells in adult brain
tissue [12–14], but these have been mainly based upon
interpretation of the morphological appearance and vascular
localization of cells found positive by immunocytochemistry, in situ
hybridization or PCR-in situ hybridization, whereas conflicting
results have been obtained in vitro from brain-derived endothelial
cells (for review, see [15]). Up until now, no study has focused on
the subject of human endothelial cell infection by HTLV-1.
Recently three membrane proteins have been described as
components of the receptor for HTLV-1 entry: the glucose
transporter Glut-1 [23], and a receptor for VEGF, Neuropilin-1
Figure 5. Productive infection of hCMEC/D3 cells by HTLV-1. (A) Kinetics of p19 viral protein secretion in the supernatant of hCMEC/D3 and
irradiated HTLV-1 MT-2 lymphocyte cocultures. Cells were cultivated or not in presence of 25 mM AZT. Results are mean and standard deviation from
triplicate experiments. (B) Kinetics of detection of infected hCMEC/D3 cells by irradiated MT-2 cells. Infection was assessed by FACS analysis of p24
viral protein at days 12, 14, 16 and 22 post-coculture. (C) Production of infectious viral particles by HTLV-1-infected endothelial cells using a reporter
cell-line (293T-LTR-GFP). The supernatant of hCMEC/D3 infected cells was collected and ultracentrifuged and the resuspended pellet was applied on
the reporter cell-line 293T-LTR-GFP. The expression of GFP was assessed 6 days later after cell fixation.
doi:10.1371/journal.ppat.1000205.g005
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[22] and heparan sulfate-proteoglycans [21,32]. Vascular expres-
sion of Glut-1 [33,34] and Neuropilin-1 [35,36] has been
previously reported within the CNS, under normal and patholog-
ical conditions. We have shown that the HTLV-1 receptors are
expressed on blood vessels of the adult human thoracic spinal
cord, a region which is characterized by BBB impairment,
lymphocyte infiltration and inflammation during HAM/TSP.
Expression of these proteins was found in endothelial cells within
the spinal cord of HAM/TSP patients, irrespective of the extent of
lymphocyte infiltration. We could also detect expression of these
receptors at the cell surface of a human cerebral endothelial cell
line, hCMEC/D3.
We then looked for HTLV-1 infected endothelial cells by in situ
hybridization using DNA probe directed against transactivator
Tax transcripts on spinal cord sections of a HAM/TSP patient.
Astrocytes are reportedly susceptible to HTLV-1 infection in vitro
[26,27]. Astrocytic infection with HTLV-1, also reported using
this technique in CNS tissues (Ozden et al. 2002), served as a
positive control in our samples. HTLV-1 transcripts were found
only very rarely associated with the vasculature. The difficulty in
detecting the virus within endothelial cells in situ may be in part
due to the specific immune response developed against HTLV-1 in
HAM/TSP patients [37]. HTLV-1 infected endothelial cells may
be detected and lysed by cytotoxic lymphocytes, thereby
Figure 6. Alteration of BBB functions in the infected hCMEC/D3 cells. (A) Altered permeability of a monolayer of infected hCMEC/D3 cells.
The endothelial cells were cocultured with irradiated MT-2 or C81-66 lymphocytes for 15 days. Then hCMEC/D3 cells were seeded on Transwell filters
and permeability to FITC-dextran 70 kDa was assessed after differentiation of the monolayer. (B) Effect of endothelial cells infection on CEM
lymphocyte migration. Infected endothelial cells were seeded onto filters. The migration was estimated at 24 hours of culture by fluorescence assay
after labeling of lymphocytes (from the CEM, Jurkat, MT-2 of C81-66 cell-lines) with a fluorescent marker. The migration rate is expressed as ratio (%)
of fluorescence intensity in the lower compartment versus total fluorescence. (C) Analysis of the expression level of ZO-1, Occludin, and viral p24 of a
monolayer of hCMEC/D3 cells cocultured with irradiated MT-2 or C81-66 for 15 days. b-tubulin was used for normalization. (D) Inhibiting MLC
phosphorylation has no effect on the permeability for FITC dextran 70 kDa across a monolayer of infected endothelial cells. hCMEC/D3 cells were
seeded on filters. After differentiation, cultures were either left untreated of treated for 48 hours with ML-1, a specific inhibitor for MLCK activity.
Permeability was then estimated as described in Materials and Methods.
doi:10.1371/journal.ppat.1000205.g006
HTLV-1 Infects Brain Endothelial Cells
PLoS Pathogens | www.plospathogens.org 7 November 2008 | Volume 4 | Issue 11 | e1000205
constituting a new mechanism for transient BBB disruption, which
remains to be explored further. Moreover, the tissue sections
studied are from a patient with a rapid progressing HAM/TSP
[4]. Additional studies in other HAM/TSP patients, with slower
disease progression, might facilitate the detection of HTLV-1-
infected endothelial cells.
As the ex vivo detection was difficult to ascertain, we studied the
susceptibility of an in vitro model, hCMEC/D3, to HTLV-1
infection. We confirmed that the expression of the receptors at the
cell surface of hCMC/D3 cells allowed viral entry. In fact, it has
been demonstrated that cholesterol, a central component of lipid
rafts, was necessary for HTLV-1 infection, especially on post-
binding entry steps [38]. Thus we examined whether the spatial
organization of viral receptors on the membrane of cerebral
endothelial cells would enable infection with HTLV. Using LacZ-
reporting viral particles pseudotyped with the HTLV envelope
[23], we demonstrated that the envelope recognized and fused
correctly with the membrane of endothelial cells. Expression of
functional receptors at the cell surface are usually also demon-
strated via the ability of target cells to form syncytia with infected
lymphocytes [39]. Syncytia were indeed formed during co-cultures
of infected lymphocytes and hCMEC/D3, and this could be
prevented by addition of serum from an HAM/TSP patient,
confirming the role of viral envelope in the process of cell-cell
fusion. Similarly, the formation of syncytia could be prevented by
addition of binding inhibitors directed to the previously described
HTLV-1 receptors, demonstrating that it is a proper receptor-
mediated entry. The death of cells forming syncytia was observed
after one week in culture, as reported for other cell types [40], but
p19 detection in the supernatant at later stages confirmed the
persistent infection of endothelial cells. The production of viral
proteins corresponds to that of the infectious virus, as shown using
293T-LTR-GFP reporter cells assays.
Of note, direct infection of cerebral endothelial cells may
constitute a new mechanism of entry for the retrovirus into the
CNS. In fact, endothelial cells and astrocytes are tightly associated
at the BBB; infected endothelial cells could then transmit infectious
particles to astrocytes, which have been shown to be susceptible to
HTLV-1 infection both in vitro and in vivo [4,26,27,41].
Finally, we analyzed the impact that infection of endothelial
cells had on BBB integrity. At day 20 following co-culture with
irradiated lymphocytes, the endothelial cells showed no cytopathic
effect and no syncytia was observed. We demonstrated that
HTLV-infected hCMEC/D3 cells could no longer form confluent
monolayers resistant to molecular diffusion and cellular migration.
Indeed, BBB dysfunction results in enhanced transendothelial
migration of both HTLV-1-infected and uninfected lymphocytes.
Both lymphocytes carrying HTLV-1 and tight junction opening
could facilitate the spread of the virus and cytotoxic lymphocytes
into the CNS. The mechanisms for such an alteration are not
completely understood and may be multifactorial. We previously
demonstrated that inflammatory cytokines produces by HTLV-1
infected lymphocytes induced BBB disruption, by increasing the
expression and activity of the Myosin Light Chain Kinase
(MLCK), which is transcriptionally regulated by the NF-kB
pathway [8]. Since Tax expression induces cytokine secretion
[42,43,44], disruption of the BBB could be a consequence of the
autocrine or paracrine effects of proinflammatory cytokines
secreted by HTLV-1 infected endothelial cells. This could explain
why a low infection rate (,20%) of the cells is sufficient to
significantly alter BBB-related functions. However, ML-7 treat-
ment (an inhibitor of MLCK activity) of virally infected
endothelial cells could not prevent such a disruption. This is
consistent with the observations of McKenzie and Ridley who
recently showed that MLCK activity is not required for long term
modification of TJ protein expression, mediated by TNFa [45].
Further investigations could focus on possible interactions
between viral Tax protein and proteins that constitute TJs. For
example, the protein ZO-1 bears a PDZ domain [46] and Tax a
PDZ binding domain [47] and suggest that these proteins interact
with each other. This interaction could induce relocalization of
ZO-1 and disorganize the TJ, or the protein could directly target
the proteasome, as Tax does for the Retinoblastoma protein [48].
In conclusion, we have shown that endothelial cells, which
constitute the BBB, are susceptible to infection by HTLV-1. This
represents a new mechanism for BBB disruption in HAM/TSP,
either directly as the expression of Tax induces a loss of BBB
functions, or indirectly as the infected endothelial cells will be
targeted by the immune system. Moreover, as the infection is
productive, endothelial cells could allow entry of the virus into the
CNS and facilitate the infection of astrocytes within the CNS
parenchyma. Some may argue that the disruption of the BBB due to
the infection of the endothelial cells seem to be a minor event in the
natural course of HAM/TSP pathogenesis when compared to the
proinflammatory cytokines [8]. However, considering this possibil-
ity should not be neglected for the design of potential new
treatments. For example, the inhibition of the VEGF has been
proposed previously as a way to prevent lymphocyte migration
throughout the vasculature [49,50]. Our results suggest that such a
treatment should be envisioned with caution in the context of BBB,
as it could increase the availability of the Neuropilin-1 to the virus
and thereby, could facilitate infection of the BBB by HTLV-1.
Materials and Methods
Cells and tissues
The human Cerebral Microvascular Endothelial Cell line,
hCMEC/D3, was immortalized after transduction with lentiviral
vectors encoding the catalytic subunit of human telomerase
hTERT and SV40 T antigen, as described previously [28].
hCMEC/D3 cells were grown in Endothelial Growth Medium-2
(EGM-2MV, Clonetics, Cambrex Biosciences, Workingham, UK)
without hydrocortisone, on Biocoat tissue culture flasks (BD
Biosciences, Bedford, MA).
MT-2 and C81-66 were used as HTLV-1-infected T cell lines.
These are cell-lines derived from human umbilical cord blood T
cells, following culture with irradiated cells from at ATLL patient.
Both cell lines express the viral transactivator Tax-1, although
C81-66 does not produce any viral particles. CEM and Jurkat
were used as uninfected control T-cell lines. Non-adherent cell
lines were grown in RPMI 1640 medium (Gibco BRL,
Gaithersburg, MD) supplemented with 1 mM glutamine and
10% FCS.
The HEK epithelial cells containing an integrated HTLV-1
long terminal repeat (LTR) coupled to a green fluorescent protein
(GFP) reporter gene (called herein 293T-LTR-GFP) [51] were
grown in Dulbecco’s modified Eagle’s medium (Gibco BRL)
supplemented with glutamine (1 mM), 100 U/ml penicillin, and
10% FCS.
Frozen tissue autopsy sections from a HAM/TSP patient were
obtained as previously described [4]. For one experiment, we used
paraffin embedded material from the thoracic spinal cord of a
HAM/TSP patient from Chile, whose case has been previously
described [52]. Frozen spinal cord tissues from uninfected control
patients were obtained from the UK Multiple Sclerosis Tissue
Bank and as previously described [53]. All tissue specimens were
obtained in accordance with the respective hospital and national
regulations and ethical rules.
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Immunohistochemistry, immunofluorescence and in situ
hybridization
Fixed frozen (4% paraformaldehyde, PFA) and snap frozen
blocks of tissues were sectioned serially at 10 mm using a cryostat;
sections were then air-dried, and fixed in methanol before
processing for immunohistochemistry. Sections were either labeled
by immunoperoxidase technique (3-step procedure, DAKO,
Glostrup, Denmark) or alcaline phosphatase technique (Vectas-
tain, Vector Laboratories, CA, USA). Endogenous peroxidase was
blocked with 2,5% hydrogen peroxidase in methanol, and non-
specific labeling blocked with normal sera corresponding to the
secondary antibody species. Sections were dehydrated in graded
alcohols, cleared in xylene and coverslipped using permount. The
primary antibodies used were a mouse antibody to Glut-1 (MAB
1418, R&D systems, Minneapolis, MN, USA), to NP-1 (clone A-
12, Santa Cruz Biotechnology, Santa Cruz, CA, USA), or to
Factor VIII (DAKO).
Cultures were fixed with 4% PFA. Staining with primary
antibody was performed after incubation for 30 minutes with 10%
normal goat serum and 0.05% saponin diluted in PBS. The
following primary antibodies were used: mouse antibodies to
HTLV-1-p24 (ab9081, Abcam, Cambridge, UK), to Glut-1 (R&D
systems), to NP-1 (Santa Cruz Biotechnology). Specific secondary
antibodies were coupled with Fluorescein (Vector Laboratories).
After washes, preparations were mounted in DAPI-containing
Vectashield medium (Vector laboratories).
ISH was performed on serial sections of frozen tissues by means
of 32P antisense and sense riboprobes corresponding to the
complete tax mRNA, as described elsewhere [54]. Sections were
stained prior to ISH by immunoperoxidase using a rabbit
polyclonal antibody against Glial Fribrillary Acidic Protein (anti-
GFAP, DAKO).
Flow cytometry analysis
Cells were analyzed for surface or intracellular receptor
expression, with or without permeabilization with triton. Cells
were resuspended in PBS-EDTA and incubated at 4uC for 30 min
with a primary antibody to NP-1, Glut-1, HSPGs (clone F69-
3G10, Seikagaku Corp., Tokyo, Japan) or HTLV-1 p24.
Secondary antibody staining was performed by incubating the
cells with fluorescein-isothiocyanate (FITC)-labeled antibody
(Vector Laboratories) at 4uC for 30 min. Cells were washed twice
with phosphate-buffered saline (PBS) and analyzed by using a
FACScan flow cytometer and Cellquest software (Becton Dick-
inson, San Jose, CA, USA).
Infection assays
Replication-defective LacZ retroviral vectors pseudotyped with
either the HTLV (H-MLV), or amphotropic murine leukemia
virus (A-MLV) envelope proteins were produced by transfection of
293T cells with Gag/Pol, Env, and LacZ plasmids as described
elsewhere [23]. Target cells were plated on 24-well plates (5.104)
for 24 h and supernatants from H-MLV (1/5), or A-MLV (1/100)
pseudotype-producing cells were added. Infectivity was assessed
48 h later by measuring the level of lacZ activity with the b-Gal
reporter gene assay kit (Roche, France).
Syncytia were obtained after 24 h coculture of hCMEC/D3
cells and MT-2 infected lymphocytes (1:1 ratio). The p24 staining
was performed by an indirect immunofluorescence assay using the
mouse anti-HTLV-1 p24 antibody on PFA fixed cells. To
ascertain the endothelial origin of the syncytia, the hCMEC/D3
cells were prelabeled with CellTrackerTM Red CMTPX (Molec-
ular Probes, Invitrogen, Carlsbad, CA, USA). The preparations
were visualized with a Zeiss Axiovert apparatus (Iena, Germany)
or Leica DMRB (Wetzlar, Germany). The syncytia formation was
inhibited by addition of dextran sulfate (100 mg/mL, Sigma
Aldrich, St Louis, MO, USA), VEGF165 (50 ng/mL, R&D
systems) or rabbit polyclonal antibody directed to Glut-1
(ab15309, Abcam; anti Cbl-b antibody H454 was used as an
irrelevant antibody).
The extent of syncytia formation was assessed after 24 h in
coculture by counting their numbers, as well as nuclei per syncytia,
using Giemsa staining. All microscopic fields from 16 mm
diameter coverslips were evaluated, from three different cultures.
For inhibition experiments, serum from a HAM/TSP patient or
control serum (lacking HTLV-1 antibodies detected by Western
blot assay) was added at the beginning of the coculture.
Chronically infected cells (MT-2 lymphocytes or C81-66 cells as
control as they can not transmit infection) were irradiated at
10 Gy and washed twice with PBS to eliminate free radicals.
hCMEC/D3 monolayers were cocultivated overnight at 37uC
with the irradiated lymphocytes at a 1:1 ratio and extensively
washed three times with medium lacking serum. Human
endothelial cell cultures were then maintained in normal culture
medium. Aliquots of culture medium were collected at different
time to detect viral proteins. HTLV-1 p19 was detected in culture
media using the HTLV p19 antigen ELISA assay (Zeptometrix,
Buffalo, NY, USA). In order to prevent the viral infection, 25 mM
of AZT, an inhibitor of the reverse transcriptase, were added to
the culture medium.
Secondary infection
Secondary infection was performed as described previously
[55]. Briefly, HCMEC/D3 cells were cocultured with irradiated
MT-2 lymphocytes (or control C81-66 cells) for 15 days. The cells
were then extensively washed and the medium replaced. Forty-
eight hours later, the growth medium was collected and clarified
by low-speed centrifugation (2,500 rpm for 5 min) then filtered
through a 45-mm filter. The resulting media was then layered on a
20% glycerol gradient and the virus in it was pelleted by
centrifugation in a SW28 rotor at 22,000 rpm for 2 h. The pellet
was then resuspended in 200 ml of serum-free DMEM. 293T-LTR
GFP indicator cells were incubated with 200 ml of the virus
suspension in a total volume of 2 ml of serum-free DMEM for 2 h.
Complete medium was then added and changed twice a week.
One week later, the cells were fixed in 4% PFA, and visualized
with a Zeiss Axiovert apparatus. The specificity of the signal was
confirmed by addition of AZT into the culture medium.
Immunoblot analyses
TJ proteins expression in HCMEC/D3 cells (cocultured for 15
days with MT-2 or C81-66 irradiated lymphocytes) was
investigated by immunoblot analysis. Cells were washed twice
with PBS, lysed in appropriate buffer (50 mM Tris-HCl,pH 7.4,
120 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 0.2 mM
Na3VO4, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride) in the presence of a cocktail of protease inhibitors (Roche
Applied Science, Indianapolis, IN, USA), and incubated on ice.
Protein concentration was determined by the Bradford method
(Bio-Rad, Hercules, CA, USA). Samples were loaded into 4–20%
Tris/Gly gels (NOVEX, Invitrogen), subjected to SDS-PAGE,
and transferred onto a nitrocellulose membrane (Immobilon-P,
Millipore, Billerica, MA, USA). Following incubation with specific
antibodies (rabbit anti ZO-1 and Occludin from Zymed or mouse
anti-HTLV-p24 from AbCam) and extensive washing in PBS-
Tween 0.05%, membranes were incubated with horseradish
peroxidase-conjugated secondary antibodies (Vector Laboratories)
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and developed using either the SuperSignal WestPico or Super-
Signal West Femto Chemiluminescent substrate kit (Pierce,
Rockford, IL, USA). To ensure equal amount of protein loaded
per well, membranes were stripped with the Re-blot Plus Kit
(Chemicon International, Temecula, CA, USA) and reprobed
with a specific anti b-tubulin antibody (Santa Cruz Biotechnology).
Endothelial permeability assays
Permeability of hCMEC/D3 cell monolayers was measured
using a method adapted from Dehouck et al. [56] and Romero et
al. [30] on Transwell-ClearTM filters (polyester, 12 mm diameter,
pore size 3 mm, Costar, Brumath, France). Briefly, 105 cells/well
were seeded on filters previously coated with rat-tail collagen I (BD
Biosciences) and bovine plasma fibronectin (Sigma Aldrich). At
confluence, hydrocortisone was added to EBM-2 medium as
recommended by the manufacturer. After 24 hours, cells were
used for experiments. Coculture experiments were set up by
adding of 105 lymphocytes to the endothelial monolayer in the
presence or absence of inhibitors.
For the permeability test, the culture medium was replaced by
DMEM without phenol red. FITC-labelled dextran (molecular
weight 70 kDa, Sigma Aldrich) was added to the upper
compartment and inserts were transferred sequentially at 5 min-
utes intervals from well to well for 30 min. The quantity of FITC-
dextran that had diffused through the monolayer into the lower
compartment at each time point was determined using a
fluorescence multiwell plate reader (Wallac VictorTM 1420,
PerkinElmer, Wellesley, MA, USA). The permeability coefficients
of the endothelial monolayers were then calculated as previously
described [30].
T-lymphocyte migration through brain endothelial
monolayers
Lymphocytes were labeled with CellTrackerTM Green BODI-
PYH (Molecular Probes) according to manufacturer’s instructions.
Labeled lymphocytes were added to the upper chamber of
Transwell-ClearTM insert filters (polyester, 12 mm diameter, pore
size 3 mm, Costar) containing confluent hCMEC/D3 monolayers.
After 24 hours at 37uC, the monolayer was extensively washed
with PBS/EDTA, in order to collect lymphocytes adherent to each
side of the membrane. Cells were lyzed using water. Fluorescence
intensity was determined using a fluorescence multiwell plate
reader.
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